68ga fapi-46 Search Results


good radiopharmaceutical practice module sc-01  (Scintomics GmbH)
90
Scintomics GmbH good radiopharmaceutical practice module sc-01
Good Radiopharmaceutical Practice Module Sc 01, supplied by Scintomics GmbH, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/good radiopharmaceutical practice module sc-01/product/Scintomics GmbH
Average 90 stars, based on 1 article reviews
good radiopharmaceutical practice module sc-01 - by Bioz Stars, 2026-02
90/100 stars
  Buy from Supplier
68 ga]ga-fapi-46  (Eckert Ziegler BEBIG GmbH)
90
Eckert Ziegler BEBIG GmbH 68 ga]ga-fapi-46
68 Ga]Ga Fapi 46, supplied by Eckert Ziegler BEBIG GmbH, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/68 ga]ga-fapi-46/product/Eckert Ziegler BEBIG GmbH
Average 90 stars, based on 1 article reviews
68 ga]ga-fapi-46 - by Bioz Stars, 2026-02
90/100 stars
  Buy from Supplier
68 ga]ga-fapi-46  (Siemens Healthineers)
90
Siemens Healthineers 68 ga]ga-fapi-46
A 62-year-old woman with intrahepatic cholangiocarcinoma underwent PET/CT with dedicated liver PET/MRI for initial staging. ( a ) MIP image of [ 68 <t>Ga]Ga-FAPI-46</t> PET, ( c ) fused axial [ 68 Ga]Ga-FAPI-46 PET/CT image, and ( e ) axial [ 68 Ga]Ga-FAPI-46 attenuation correction PET image show a lesion with intense uptake (SUVmax = 24.02, TBR = 21.07) in the liver (arrows) corresponding to the primary liver cancer. ( b ) MIP [ 18 F]FDG PET image, ( d ) fused axial [ 18 F]FDG PET/CT images, and ( f ) axial [ 18 F]FDG PET attenuation-corrected PET image show less tracer uptake than [ 68 Ga]Ga-FAPI-46 PET (SUVmax = 15.79, TBR = 4.97) in the corresponding liver lesions (arrows). The corresponding axial MR images show a mass in hepatic segments VI/VII with adjacent intrahepatic bile duct dilatation. This lesion shows delayed enhancement ( g , h ) and restricted diffusion on ( i ) DWI/ADC images.
68 Ga]Ga Fapi 46, supplied by Siemens Healthineers, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/68 ga]ga-fapi-46/product/Siemens Healthineers
Average 90 stars, based on 1 article reviews
68 ga]ga-fapi-46 - by Bioz Stars, 2026-02
90/100 stars
  Buy from Supplier
68ga]-fapi-46 pet imaging  (ClinTec Inc)
90
ClinTec Inc 68ga]-fapi-46 pet imaging
A 62-year-old woman with intrahepatic cholangiocarcinoma underwent PET/CT with dedicated liver PET/MRI for initial staging. ( a ) MIP image of [ 68 <t>Ga]Ga-FAPI-46</t> PET, ( c ) fused axial [ 68 Ga]Ga-FAPI-46 PET/CT image, and ( e ) axial [ 68 Ga]Ga-FAPI-46 attenuation correction PET image show a lesion with intense uptake (SUVmax = 24.02, TBR = 21.07) in the liver (arrows) corresponding to the primary liver cancer. ( b ) MIP [ 18 F]FDG PET image, ( d ) fused axial [ 18 F]FDG PET/CT images, and ( f ) axial [ 18 F]FDG PET attenuation-corrected PET image show less tracer uptake than [ 68 Ga]Ga-FAPI-46 PET (SUVmax = 15.79, TBR = 4.97) in the corresponding liver lesions (arrows). The corresponding axial MR images show a mass in hepatic segments VI/VII with adjacent intrahepatic bile duct dilatation. This lesion shows delayed enhancement ( g , h ) and restricted diffusion on ( i ) DWI/ADC images.
68ga] Fapi 46 Pet Imaging, supplied by ClinTec Inc, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/68ga]-fapi-46 pet imaging/product/ClinTec Inc
Average 90 stars, based on 1 article reviews
68ga]-fapi-46 pet imaging - by Bioz Stars, 2026-02
90/100 stars
  Buy from Supplier

Image Search Results


A 62-year-old woman with intrahepatic cholangiocarcinoma underwent PET/CT with dedicated liver PET/MRI for initial staging. ( a ) MIP image of [ 68 Ga]Ga-FAPI-46 PET, ( c ) fused axial [ 68 Ga]Ga-FAPI-46 PET/CT image, and ( e ) axial [ 68 Ga]Ga-FAPI-46 attenuation correction PET image show a lesion with intense uptake (SUVmax = 24.02, TBR = 21.07) in the liver (arrows) corresponding to the primary liver cancer. ( b ) MIP [ 18 F]FDG PET image, ( d ) fused axial [ 18 F]FDG PET/CT images, and ( f ) axial [ 18 F]FDG PET attenuation-corrected PET image show less tracer uptake than [ 68 Ga]Ga-FAPI-46 PET (SUVmax = 15.79, TBR = 4.97) in the corresponding liver lesions (arrows). The corresponding axial MR images show a mass in hepatic segments VI/VII with adjacent intrahepatic bile duct dilatation. This lesion shows delayed enhancement ( g , h ) and restricted diffusion on ( i ) DWI/ADC images.

Journal: Molecular Imaging and Biology

Article Title: Comparisons of Quantitative Parameters of Ga-68-Labelled Fibroblast Activating Protein Inhibitor (FAPI) PET/CT and [ 18 F]F-FDG PET/CT in Patients with Liver Malignancies

doi: 10.1007/s11307-022-01732-2

Figure Lengend Snippet: A 62-year-old woman with intrahepatic cholangiocarcinoma underwent PET/CT with dedicated liver PET/MRI for initial staging. ( a ) MIP image of [ 68 Ga]Ga-FAPI-46 PET, ( c ) fused axial [ 68 Ga]Ga-FAPI-46 PET/CT image, and ( e ) axial [ 68 Ga]Ga-FAPI-46 attenuation correction PET image show a lesion with intense uptake (SUVmax = 24.02, TBR = 21.07) in the liver (arrows) corresponding to the primary liver cancer. ( b ) MIP [ 18 F]FDG PET image, ( d ) fused axial [ 18 F]FDG PET/CT images, and ( f ) axial [ 18 F]FDG PET attenuation-corrected PET image show less tracer uptake than [ 68 Ga]Ga-FAPI-46 PET (SUVmax = 15.79, TBR = 4.97) in the corresponding liver lesions (arrows). The corresponding axial MR images show a mass in hepatic segments VI/VII with adjacent intrahepatic bile duct dilatation. This lesion shows delayed enhancement ( g , h ) and restricted diffusion on ( i ) DWI/ADC images.

Article Snippet: [ 68 Ga]Ga-FAPI-46 PET imaging was performed on a 64-slice Siemens Biograph vision scanner (Siemens Healthineers, Erlangen, Germany) after intravenous injection of 2.59 MBq/kg of [ 68 Ga]Ga-FAPI-46 over approximately 60 min. Non-contrast-enhanced CT was also acquired for attenuation correction (kV = 120, effective mAs = 25, Care Dose 4D, quality reference = 70).

Techniques: Positron Emission Tomography-Computed Tomography, Diffusion-based Assay

A 50-year-old man with elevated AFP concentration underwent PET/CT with dedicated liver PET/MRI for diagnostic purposes. ( a ) MIP [ 68 Ga]Ga-FAPI-46 PET image, ( c ) coronal fused [ 68 Ga]Ga-FAPI-46 PET/CT image, ( f ) axial [ 68 Ga]Ga-FAPI-46 attenuation-corrected PET image, and ( h ) axial fused [ 68 Ga]Ga-FAPI-46 PET/CT image showing lesions with intense uptake (SUVmax = 8.3, TBR = 7.90) corresponding to the heterogeneous enhancing nodules in segment II (arrow) on ( e ) coronal delayed gadoxetate disodium–enhanced MRI. ( b ) MIP [ 18 F]FDG PET image, ( d ) coronal fused [ 18 F]FDG PET/CT image, ( g ) axial [ 18 F]FDG attenuation-corrected PET image, and ( i ) axial fused [ 18 F]FDG PET/CT image do not show these primary tumours because of the low level of uptake and obscuring adjacent gastric activity (arrow dot) (SUVmax = 3.37, TBR = 1.25).

Journal: Molecular Imaging and Biology

Article Title: Comparisons of Quantitative Parameters of Ga-68-Labelled Fibroblast Activating Protein Inhibitor (FAPI) PET/CT and [ 18 F]F-FDG PET/CT in Patients with Liver Malignancies

doi: 10.1007/s11307-022-01732-2

Figure Lengend Snippet: A 50-year-old man with elevated AFP concentration underwent PET/CT with dedicated liver PET/MRI for diagnostic purposes. ( a ) MIP [ 68 Ga]Ga-FAPI-46 PET image, ( c ) coronal fused [ 68 Ga]Ga-FAPI-46 PET/CT image, ( f ) axial [ 68 Ga]Ga-FAPI-46 attenuation-corrected PET image, and ( h ) axial fused [ 68 Ga]Ga-FAPI-46 PET/CT image showing lesions with intense uptake (SUVmax = 8.3, TBR = 7.90) corresponding to the heterogeneous enhancing nodules in segment II (arrow) on ( e ) coronal delayed gadoxetate disodium–enhanced MRI. ( b ) MIP [ 18 F]FDG PET image, ( d ) coronal fused [ 18 F]FDG PET/CT image, ( g ) axial [ 18 F]FDG attenuation-corrected PET image, and ( i ) axial fused [ 18 F]FDG PET/CT image do not show these primary tumours because of the low level of uptake and obscuring adjacent gastric activity (arrow dot) (SUVmax = 3.37, TBR = 1.25).

Article Snippet: [ 68 Ga]Ga-FAPI-46 PET imaging was performed on a 64-slice Siemens Biograph vision scanner (Siemens Healthineers, Erlangen, Germany) after intravenous injection of 2.59 MBq/kg of [ 68 Ga]Ga-FAPI-46 over approximately 60 min. Non-contrast-enhanced CT was also acquired for attenuation correction (kV = 120, effective mAs = 25, Care Dose 4D, quality reference = 70).

Techniques: Concentration Assay, Positron Emission Tomography-Computed Tomography, Diagnostic Assay, Activity Assay

A 78-year-old man with intrahepatic cholangiocarcinoma who underwent left hepatectomy and chemotherapy approximately 3 years earlier (last chemotherapy session approximately 3 months prior to imaging). The patient underwent PET/CT with dedicated liver PET/MRI for restaging. ( b ) Whole-body [ 68 Ga]Ga-FAPI-46 PET maximum-intensity-projection (MIP) image showing multiple intense FAPI-avid nodules (arrows) in the liver corresponding to multiple heterogeneous enhancing nodules ( e ) with fluid restriction on axial fused [ 68 Ga]Ga-FAPI-46 PET/MRI of the liver ( f ); liver metastases were likely. ( a ) [ 18 F]FDG PET MIP image showing only subtle uptake at the hepatic dome. Three months later, the patient underwent PET/CT for re-evaluation of disease: ( d ) [ 68 Ga]Ga-FAPI-46 PET MIP image; ( g ) axial gadolinium-enhanced MRI image; ( h ) axial fused [ 68 Ga]Ga-FAPI-46 PET/MRI of the liver. Follow-up [ 68 Ga]Ga-FAPI-46 PET/CT with dedicated liver PET/MRI shows that the previous FAPI-46-avid nodules in the residual liver have increased in size and intensity. ( c ) The paired [ 18 F]FDG PET MIP image shows a few new FDG-avid nodules (arrows) in the liver, confirming the diagnosis of viable liver metastases in the study 3 months previous.

Journal: Molecular Imaging and Biology

Article Title: Comparisons of Quantitative Parameters of Ga-68-Labelled Fibroblast Activating Protein Inhibitor (FAPI) PET/CT and [ 18 F]F-FDG PET/CT in Patients with Liver Malignancies

doi: 10.1007/s11307-022-01732-2

Figure Lengend Snippet: A 78-year-old man with intrahepatic cholangiocarcinoma who underwent left hepatectomy and chemotherapy approximately 3 years earlier (last chemotherapy session approximately 3 months prior to imaging). The patient underwent PET/CT with dedicated liver PET/MRI for restaging. ( b ) Whole-body [ 68 Ga]Ga-FAPI-46 PET maximum-intensity-projection (MIP) image showing multiple intense FAPI-avid nodules (arrows) in the liver corresponding to multiple heterogeneous enhancing nodules ( e ) with fluid restriction on axial fused [ 68 Ga]Ga-FAPI-46 PET/MRI of the liver ( f ); liver metastases were likely. ( a ) [ 18 F]FDG PET MIP image showing only subtle uptake at the hepatic dome. Three months later, the patient underwent PET/CT for re-evaluation of disease: ( d ) [ 68 Ga]Ga-FAPI-46 PET MIP image; ( g ) axial gadolinium-enhanced MRI image; ( h ) axial fused [ 68 Ga]Ga-FAPI-46 PET/MRI of the liver. Follow-up [ 68 Ga]Ga-FAPI-46 PET/CT with dedicated liver PET/MRI shows that the previous FAPI-46-avid nodules in the residual liver have increased in size and intensity. ( c ) The paired [ 18 F]FDG PET MIP image shows a few new FDG-avid nodules (arrows) in the liver, confirming the diagnosis of viable liver metastases in the study 3 months previous.

Article Snippet: [ 68 Ga]Ga-FAPI-46 PET imaging was performed on a 64-slice Siemens Biograph vision scanner (Siemens Healthineers, Erlangen, Germany) after intravenous injection of 2.59 MBq/kg of [ 68 Ga]Ga-FAPI-46 over approximately 60 min. Non-contrast-enhanced CT was also acquired for attenuation correction (kV = 120, effective mAs = 25, Care Dose 4D, quality reference = 70).

Techniques: Imaging, Positron Emission Tomography-Computed Tomography

A 67-year-old man with cholangiocarcinoma underwent right hepatectomy with right adrenal gland, gallbladder, and diaphragm resection approximately 1 year earlier. He also received chemotherapy (last session approximately 6 months prior to imaging) and underwent PET/CT for restaging. ( a ) [ 68 Ga]Ga-FAPI-46 PET MIP image; ( c ) axial conventional CT image; and ( d ) fused [ 68 Ga]Ga-FAPI-46 PET/CT images show an FAPI-avid nodule (arrow) in the right high parasagittal frontal area with perilesional brain oedema; brain metastasis was suspected and was confirmed on follow-up brain MRI. This brain metastasis was barely detectable on FDG PET. ( b ) FDG PET MIP image; ( e ) fused axial FDG PET/CT. Further brain radiotherapy treatment was scheduled. Multiple pulmonary and subpleural nodules (arrow dot) with FDG and FAPI uptake are scattered in both lungs on ( a ), ( b ), ( f ) axial conventional CT image; ( g ), fused axial [ 68 Ga]Ga-FAPI-46 PET/CT; and ( h ), fused axial FDG PET/CT.

Journal: Molecular Imaging and Biology

Article Title: Comparisons of Quantitative Parameters of Ga-68-Labelled Fibroblast Activating Protein Inhibitor (FAPI) PET/CT and [ 18 F]F-FDG PET/CT in Patients with Liver Malignancies

doi: 10.1007/s11307-022-01732-2

Figure Lengend Snippet: A 67-year-old man with cholangiocarcinoma underwent right hepatectomy with right adrenal gland, gallbladder, and diaphragm resection approximately 1 year earlier. He also received chemotherapy (last session approximately 6 months prior to imaging) and underwent PET/CT for restaging. ( a ) [ 68 Ga]Ga-FAPI-46 PET MIP image; ( c ) axial conventional CT image; and ( d ) fused [ 68 Ga]Ga-FAPI-46 PET/CT images show an FAPI-avid nodule (arrow) in the right high parasagittal frontal area with perilesional brain oedema; brain metastasis was suspected and was confirmed on follow-up brain MRI. This brain metastasis was barely detectable on FDG PET. ( b ) FDG PET MIP image; ( e ) fused axial FDG PET/CT. Further brain radiotherapy treatment was scheduled. Multiple pulmonary and subpleural nodules (arrow dot) with FDG and FAPI uptake are scattered in both lungs on ( a ), ( b ), ( f ) axial conventional CT image; ( g ), fused axial [ 68 Ga]Ga-FAPI-46 PET/CT; and ( h ), fused axial FDG PET/CT.

Article Snippet: [ 68 Ga]Ga-FAPI-46 PET imaging was performed on a 64-slice Siemens Biograph vision scanner (Siemens Healthineers, Erlangen, Germany) after intravenous injection of 2.59 MBq/kg of [ 68 Ga]Ga-FAPI-46 over approximately 60 min. Non-contrast-enhanced CT was also acquired for attenuation correction (kV = 120, effective mAs = 25, Care Dose 4D, quality reference = 70).

Techniques: Imaging, Positron Emission Tomography-Computed Tomography

Images from a 66-year-old woman with cholangiocarcinoma who underwent chemotherapy (last session approximately 3 months prior to imaging). The patient underwent PET/CT with dedicated liver PET/MRI for restaging. ( a ) [ 68 Ga]Ga-FAPI-46 PET MIP image; ( c ) coronal fused [ 68 Ga]Ga-FAPI-46 PET/CT image; ( e ) coronal delayed gadolinium-enhanced MRI; ( f ) coronal fused [ 68 Ga]Ga-FAPI-46 PET/MRI image. [ 68 Ga]Ga-FAPI-46 PET/CT images show a liver mass (arrow) with intense uptake corresponding to a peripheral gradually enhancing mass involving hepatic segments II, III, and IV on PET/MRI. ( b ) FDG PET MIP image and ( d ) coronal fused [ 18 F]FDG PET/CT do not show the residual viable tumour, which affected this patient’s management.

Journal: Molecular Imaging and Biology

Article Title: Comparisons of Quantitative Parameters of Ga-68-Labelled Fibroblast Activating Protein Inhibitor (FAPI) PET/CT and [ 18 F]F-FDG PET/CT in Patients with Liver Malignancies

doi: 10.1007/s11307-022-01732-2

Figure Lengend Snippet: Images from a 66-year-old woman with cholangiocarcinoma who underwent chemotherapy (last session approximately 3 months prior to imaging). The patient underwent PET/CT with dedicated liver PET/MRI for restaging. ( a ) [ 68 Ga]Ga-FAPI-46 PET MIP image; ( c ) coronal fused [ 68 Ga]Ga-FAPI-46 PET/CT image; ( e ) coronal delayed gadolinium-enhanced MRI; ( f ) coronal fused [ 68 Ga]Ga-FAPI-46 PET/MRI image. [ 68 Ga]Ga-FAPI-46 PET/CT images show a liver mass (arrow) with intense uptake corresponding to a peripheral gradually enhancing mass involving hepatic segments II, III, and IV on PET/MRI. ( b ) FDG PET MIP image and ( d ) coronal fused [ 18 F]FDG PET/CT do not show the residual viable tumour, which affected this patient’s management.

Article Snippet: [ 68 Ga]Ga-FAPI-46 PET imaging was performed on a 64-slice Siemens Biograph vision scanner (Siemens Healthineers, Erlangen, Germany) after intravenous injection of 2.59 MBq/kg of [ 68 Ga]Ga-FAPI-46 over approximately 60 min. Non-contrast-enhanced CT was also acquired for attenuation correction (kV = 120, effective mAs = 25, Care Dose 4D, quality reference = 70).

Techniques: Imaging, Positron Emission Tomography-Computed Tomography